Aggrastat Drug Interactions

Aggrastat has been studied on a background of aspirin and heparin.
The use of Aggrastat, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see Side Effects). Caution should be employed when Aggrastat is used with other drugs that affect hemostasis (e.g. warfarin) (see Bleeding Precautions under Precautions).
Aggrastat has been used concomitantly in clinical studies with beta-blockers, calcium channel blockers, non-steroidal anti-inflammatory agents (NSAIDs) and nitrate preparations without evidence of clinically significant adverse interactions.
In a sub-set of patients (n=762) in the PRISM study (Platelet Receptor Inhibition for Ischemic Syndrome Management), the plasma clearance of tirofiban in patients receiving one of the following drugs was compared to that in patients not receiving that drug. There were no clinically significant interactions of these drugs on the plasma clearance of tirofiban: acebutolol, acetaminophen, alprazolam, amlodipine, aspirin preparations, atenolol, bromazepam, captopril, diazepam, digoxin, diltiazem, docusate sodium, enalapril, furosemide, glyburide, heparin, insulin, isosorbide, levothyroxine, lorazepam, lovastatin, metoclopramide, metoprolol, morphine, nifedipine, nitrate preparations, omeprazole, oxazepam, potassium chloride, propranolol, ranitidine, simvastatin, sucralfate and temazepam.